Product
Cretostimogene Grenadenorepvec
Aliases
CG0070
3 clinical trials
3 indications
Indication
Non-Muscle-Invasive Bladder CancerIndication
Urologic CancerIndication
Bladder CancerClinical trial
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)Status: Recruiting, Estimated PCD: 2027-12-24